PALLIATIVE ASSESSMENT COHORT IN THE GERIATRIC EMERGENCY SETTING
NCT ID: NCT06911411
Last Updated: 2025-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
300 participants
OBSERVATIONAL
2025-04-01
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The PALMA cohort investigates the applicability of systematic palliative assessment (EORTC-C15 PAL) in the geriatric emergency setting combined with measures of frailty, socio-demographic risks, and cross-sectoral healthcare support.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Elderly Patients in Need of Palliative Care by Family Physicians
NCT04010136
IssuEs in Palliative Care for People in Advanced and Terminal Stages of Young-onset and Late-Onset Dementia in GErmany
NCT03364179
Timing of Acute Palliative Care Consultation in Critically Ill Patients
NCT02858778
Enhancing Palliative Care in ICU
NCT06605079
Follow Home Visits After Discharge
NCT02318680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PALMA is an implementation research project and classified as T3 on the translational scale. Inspired by The Medical Research Council (MRC), the intervention is developed through the involvement of relevant stakeholders, including patients and relatives, to ensure relevance. In addition, the feasibility is tested in a comprehensive feasibility study with a view to adapting to already established workflows.
The PALMA cohort is aimed at the part of the intervention development that will develop a stratification tool for identifying older people at risk of dying within 180 days, as well as the algorithm that will define the weight of the cross-sectoral communication regarding identified palliative needs and hospital-outgoing activities for relief.
Establishing a cohort enables to measure the EORTC-C15 PAL and Clinical Frailty Scale (CFS) applicability to the geriatric population of interest. Data are intended to inform risk stratification in a following implementation feasibility study. In PALMA we intend to identify elderly with high risk of dying within three months.
By potentially adding a time-consuming process of palliative assessment and management to a considerable workload at the geriatric emergency department is likely to act as a barrier for implementation. Hence, a non-time-consuming risk stratification process must be identified, which forms the objective of the PALMA cohort study.
In previous studies we have shown frailty, measures by CFS to be a moderate predictor of 90-day mortality and may along with immobilization status serve as quick and reliable identifier of patients at risk of dying within 90 or 180 days. The EORTC-C15 PAL is a key validated European instrument to measure patients' palliative needs. It has mostly been tested in patients in Specialised Palliative Care units and thus, we do not know if the instrument is meaningful to uncover palliative care needs in geriatric patients.
Likewise, we do not know whether the EORTC-C15 PAL corresponds with the degree of frailty or severe immobility at an acute hospital admission at the emergency department. But across various common diseases, we do know that underlying sociodemographic inequality factors and premises may mediate increased mortality and health care utilization considerably.
Cohort methodology: To answer the research question of whether frailty and/or immobility may significantly identify patients with palliative care needs the association (regression coefficient and/or relative risk) and the area under receiver operating characteristic (AUROC) curve between the assumed risk assessment tools and high score of EORTC-C15 PAL is investigated in a cross-sectional cohort design. Further, the cohort is followed for 90-day mortality to test the association between EORTC-C15 PAL scores and mortality in acutely admitted geriatric patients. (See table I for more specific question asked).
Question asked:
1. What is the association between EORTC-C15 PAL scores, CFS and immobility, and how are these associations mediated by sociodemographic characteristics?
2. May CFS/immobility assessment be used as quick screening tool for high symptom risk stratification?
With a total sample size of 198 patients (99 frail and 99 non-frail), the study will have a power of 80% at an alpha of 0.05% to detect a minimum clinically relevant difference of 10 points on PRO-PAL symptom scales. To meet 10% dropout, 10% of PRO-PAL possibly being filled out inappropriately due to severe cognitive impairment and securing 99 frail patients in a consecutive inclusion design, the total sample size of the cohort is set at 300 patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Palliative assessment group of acutely admitted older patients
Prospective observational cohort study.
No systematic approach exists for symptom assessment, management, and reporting in delivered basic palliative care within the Danish healthcare system, implying considerable variation in hospital-based palliative care. The PALMA study consists of two superior phases divided in a development and an implementation stage that anchors basic palliative assessment and management within existing geriatric workflows and cross-sectoral collaborative care.
The PALMA cohort will test the applicability of the EORTC-C15-PAL questionnaire along with measures of clinical frailty and sociodemographic risk factors.
The development phase will enable the development of a clinical algorithm for elderly patients' need for cross-sectoral palliation care planning.
A prospective observational cohort study
Observational design
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prospective observational cohort study.
No systematic approach exists for symptom assessment, management, and reporting in delivered basic palliative care within the Danish healthcare system, implying considerable variation in hospital-based palliative care. The PALMA study consists of two superior phases divided in a development and an implementation stage that anchors basic palliative assessment and management within existing geriatric workflows and cross-sectoral collaborative care.
The PALMA cohort will test the applicability of the EORTC-C15-PAL questionnaire along with measures of clinical frailty and sociodemographic risk factors.
The development phase will enable the development of a clinical algorithm for elderly patients' need for cross-sectoral palliation care planning.
A prospective observational cohort study
Observational design
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Danish Health Authority
UNKNOWN
University Hospital Bispebjerg and Frederiksberg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Trine Herskind Hasløv
Project leader
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Capital Region DK P-2023-15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.